Adrenocortical carcinoma: presentation and outcome of a contemporary patient series

dc.contributor.authorIiro Kostiainen
dc.contributor.authorLiisa Hakaste
dc.contributor.authorPekka Kejo
dc.contributor.authorHelka Parviainen
dc.contributor.authorTiina Laine
dc.contributor.authorEliisa Löyttyniemi
dc.contributor.authorMirkka Pennanen
dc.contributor.authorJohanna Arola
dc.contributor.authorCaj Haglund
dc.contributor.authorIlkka Heiskanen
dc.contributor.authorCamilla Schalin-Jäntti
dc.contributor.organizationfi=biostatistiikka|en=Biostatistics|
dc.contributor.organization-code1.2.246.10.2458963.20.89365200099
dc.converis.publication-id40315970
dc.converis.urlhttps://research.utu.fi/converis/portal/Publication/40315970
dc.date.accessioned2022-10-28T12:39:13Z
dc.date.available2022-10-28T12:39:13Z
dc.description.abstract<p>Background: Adrenocortical carcinoma (ACC) is a rare endocrine carcinoma with poor 5-year survival rates of < 40%. According to the literature, ACC is rarely an incidental imaging finding. However, presentation, treatment and outcome may differ in modern series.<br /><br />Design and methods: We studied all patients (n = 47, four children) from a single centre during years 2002–2018. We re-evaluated radiologic and histopathological findings and assessed treatments and outcome. We searched for possible TP53 gene defects and assessed nationwide incidence of ACC.<br /><br />Results: In adults, incidental radiologic finding led to diagnosis in 79% at median age of 61 years. ENSAT stage I, II, III and IV was 19%, 40%, 19% and 21%, respectively. Nonenhanced CT demonstrated > 20 Hounsfield Units (HU) for all tumours (median 34 (21–45)), median size 92 mm (20–196), Ki67 17% (1–40%), Weiss score 7 (4–9) and Helsinki score 24 (4–48). ACC was more often found in the left than the right adrenal (p < 0.05). One child had Beckwith-Wiedemann and one a TP53 mutation. In adults, the primary tumour was resected in 88 and 79% received adjuvant mitotane therapy. Median hospital stay was significantly shorter in the laparoscopic vs. open surgery group (4 (3–7) vs. 8 (5–38) days, respectively; p < 0.001). In 3/4 patients, prolonged remission of > 5 to > 10 years was achieved after repeated surgery of metastases. Overall 5-year survival was 67%, and 96% vs. 26% for ENSAT stage I–II vs. III–IV (p < 0.0001). ENSAT stage and Ki67 predicted survival, type of surgery did not. Mitotane associated with better survival.<br /><br />Conclusions: Contemporary ACC predominantly presents as an incidental imaging finding, characterised by HU > 20 on nonenhanced CT but variable tumour size (20–196 mm). Malignancy cannot be ruled out by small tumour size only. The 5-year survival of 96% in ENSAT stage I–III compares favourably to previous studies.<br /></p>
dc.format.pagerange166
dc.format.pagerange174
dc.identifier.eissn1559-0100
dc.identifier.jour-issn1355-008X
dc.identifier.olddbid177987
dc.identifier.oldhandle10024/161081
dc.identifier.urihttps://www.utupub.fi/handle/11111/35257
dc.identifier.urlhttps://link.springer.com/article/10.1007/s12020-019-01918-9
dc.identifier.urnURN:NBN:fi-fe2021042825674
dc.language.isoen
dc.okm.affiliatedauthorLöyttyniemi, Eliisa
dc.okm.discipline3121 Internal medicineen_GB
dc.okm.discipline3121 Sisätauditfi_FI
dc.okm.internationalcopublicationnot an international co-publication
dc.okm.internationalityInternational publication
dc.okm.typeA1 ScientificArticle
dc.publisherHumana Press Inc.
dc.publisher.countryUnited Statesen_GB
dc.publisher.countryYhdysvallat (USA)fi_FI
dc.publisher.country-codeUS
dc.relation.doi10.1007/s12020-019-01918-9
dc.relation.ispartofjournalEndocrine
dc.relation.issue1
dc.relation.volume65
dc.source.identifierhttps://www.utupub.fi/handle/10024/161081
dc.titleAdrenocortical carcinoma: presentation and outcome of a contemporary patient series
dc.year.issued2019

Tiedostot

Näytetään 1 - 1 / 1
Ladataan...
Name:
Kostiainen2019_Article_AdrenocorticalCarcinomaPresent.pdf
Size:
891.73 KB
Format:
Adobe Portable Document Format
Description:
Publisher's PDF